Results 221 to 230 of about 1,824,368 (348)

TRPM8 levels determine tumor vulnerability to channel agonists

Molecular Oncology, EarlyView.
TRPM8 is a Ca2+ permissive channel. Regardless of the amount of its transcript, high levels of TRPM8 protein mark different tumors, including prostate, breast, colorectal, and lung carcinomas. Targeting TRPM8 with channel agonists stimulates inward calcium currents followed by emptying of cytosolic Ca2+ stores in cancer cells.
Alessandro Alaimo, Francesco Giuseppe Carbone, Kristi Buzo, Nicole Annesi, Sacha Genovesi, Annalisa Lorenzato, Karen Widmann, Michela Libergoli, Elisa Marmocchi, Giovanni Bertalot, Alberto Brolese, Mauro Giulio Papotti, Luca Molinaro, Orazio Caffo, Mattia Barbareschi, Alberto Bardelli, Alessandro Romanel, Sabrina Arena, Andrea Lunardi   +18 more
wiley   +1 more source

Incidence of positive genetic testing among patients referred for cardiac positron emission tomography. [PDF]

J Med Genet
Trinh K, Dries A, Boulier K, Wang J.
europepmc   +1 more source

Genetic Counselling and Testing for Hereditary Breast and Ovarian Cancer: The Gent(le) Approach [PDF]

, 1999
Michel De Vos, Bruce Poppe, Immle Delvaux, Geert Mortier, Kathleen Claes, Ludwine Messiaen, Anne De Paepe   +6 more
openalex   +1 more source

The anticancer effect of the HDAC inhibitor belinostat is enhanced by inhibitors of Bcl‐xL or Mcl‐1 in ovarian cancer

Molecular Oncology, EarlyView.
The pan‐HDAC inhibitor belinostat increases the expression of the pro‐apoptotic proteins Bim, Puma, and Noxa and induces apoptosis in ovarian cancer cell lines and patient‐derived tumor organoids when used at high concentrations. Moreover, inhibiting the anti‐apoptotic proteins Bcl‐xL or Mcl‐1 sensitizes these preclinical models to the cytotoxic effect
Cécilia Thomine, Sterenn Guillemot, Louis‐Bastien Weiswald, Romane Florent, Edwige Abeilard, Florence Giffard, Emilie Brotin, Mélanie Briand, Enora Dolivet, Laurent Poulain, Marie Villedieu   +10 more
wiley   +1 more source

The attitudes of individuals with or at risk of adult-onset genetic conditions on reproductive genetic testing: A systematic review. [PDF]

J Genet Couns
Allen S, McNeill A, McDermott C, Boardman F, Howard J.   +4 more
europepmc   +1 more source

Are We Failing in Molecular Genetic Testing? [PDF]

, 1999
Robert A. Robinson
openalex   +1 more source

Systematic profiling of cancer‐fibroblast interactions reveals drug combinations in ovarian cancer

Molecular Oncology, EarlyView.
Fibroblasts, cells in the tumor environment, support ovarian cancer cell growth and alter morphology and drug response. We used fibroblast and cancer cell co‐culture models to test 528 drugs and discovered new drugs for combination treatment. We showed that adding Vorinostat or Birinapant to standard chemotherapy may improve drug response, suggesting ...
Greta Gudoityte, Osheen Sharma, Laura Leuenberger, Emelie Wallin, Josefin Fernebro, Päivi Östling, Rebecka Bergström, Johan Lindberg, Ulrika Joneborg, Olli Kallioniemi, Brinton Seashore‐Ludlow   +10 more
wiley   +1 more source

Health care providers’ experiences with genetic testing in patients at risk for hereditary angioedema

Journal of Allergy and Clinical Immunology: Global
Background: Identification of additional types of hereditary angioedema (HAE) with a normal level of C1 esterase inhibitor has highlighted the role of genetic testing in the diagnosis and management of HAE.
Dawn A. Laney, MS, Tricia D. Lee, MD, Jared Druss, BS, Ruth L. O’Keefe, BA, Patti Engel, RN, Marc Riedl, MD, MS   +5 more
doaj  

Clinical Application of Genetic Testing in Nephrology. [PDF]

Indian J Nephrol
Jeemon G, Jayram JK, Ganesh K, Kumar JS, Simon S, Abraham MA.   +5 more
europepmc   +1 more source

Genetic testing for colon cancer susceptibility: Anticipated reactions of patients and challenges to providers [PDF]

, 1996
Caryn Lerman, John C. Marshall, Janet Audrain, Andres Gomez‐Caminero   +3 more
openalex   +1 more source